130P Neutrophil-to-lymphocyte ratio as a response predictor to immune checkpoint inhibitors in non-small cell lung cancer

Abstract

patients had to withdraw owing to financial toxicity while they were still responding with average time to withdrawal being 7.2 months. Conclusions: This observational study depicts the real world scenario of the difficulties in bringing approved regimen into practice with financial toxicity being the reason the non usage in nearly 60% patients. In low income countries, this needs to be addressed if more number of patients are to be benefitted from IO agents in NSCLC.